Improvement in clinical markers in CF patients using a reduced glutathione regimen: An uncontrolled, observational study

Journal of Cystic Fibrosis

Volumn 7, Issue 5, 2008, Pages 433-436

  Visca, Alfredo ^a   Bishop, Clark T ^b   Hilton, Sterling C ^c   Hudson, Valerie M ^c  

^a ASL Cuneo 1   (Italy)

^b Brigham Young University ^*

^c BRIGHAM YOUNG UNIVERSITY   (United States)

Author keywords

BMI; FEV1; Inflammation; Pseudomonas aeruginosa; Weight percentile

Indexed keywords

BACTERIUM ANTIBODY; CACHEXON; GLUTATHIONE; RIDUTOX;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BACTERIUM CULTURE; BODY MASS; BODY WEIGHT; CHEST TIGHTNESS; CHILD; CLINICAL ARTICLE; CYSTIC FIBROSIS; DIARRHEA; DISEASE MARKER; DRUG DOSE INCREASE; DRUG FEVER; FEMALE; FORCED EXPIRATORY VOLUME; GRAM NEGATIVE INFECTION; HUMAN; LUNG FUNCTION; MALE; OBSERVATIONAL STUDY; PSEUDOMONAS AERUGINOSA; SIDE EFFECT; SPUTUM CULTURE;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; GLUTATHIONE; HUMANS; INFANT; ITALY; MALE; OBSERVATION; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME; UNITED STATES;

EID: 51549090573     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2008.03.006     Document Type: Article

References (32)

1. Linsdell P., and Hanrahan J.W. Glutathione permeability of CFTR. Am J Physiol Cell Physiol 44 1 (July 1998) C323-C326
2. Gao L., Kim K.J., Yankaskas J.R., and Forman H.J. Abnormal glutathione transport in cystic fibrosis airway epithelia. Am J Physiol Lung Cell Mol Physiol 277 1 (Jul 1999) L113-L118
3. Velsor L.W., van Heeckeren A., and Day B.J. Antioxidant imbalance in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am J Physiol Lung Cell Mol Physiol 281 1 (Jul 2001) L31-L38
4. Day B.J., van Heeckeren A.M., Min E., and Velsor L.W. Role for cystic fibrosis transmembrane conductance regulator protein in a glutathione response to bronchopulmonary pseudomonas infection. Infect Immun 72 4 (Apr 2004) 2045-2051
5. Kogan I., Ramjeesingh M., Kidd J., Li C., Wang Y., and Bear C.E. Characterization of glutathione permeability through the CFTR channel pore. Ped Pulmonol 24 (Oct 2002) 189-190
6. Kogan I., Ramjessingh M., Li C., Kidd J.F., Wang Y., Leslie E.M., Cole S.P.C., and Bear C.E. CFTR directly mediates nucleotide-regulated glutathione flux. EMBO 22 9 (May 1 2003) 1981-1989
7. Kariya C., Leitner H., Min E., van Heeckeren C., van Heeckeren A., and Day B.J. A role for CFTR in the elevation of glutathione in the lung by oral glutathione administrations. Am J Physiol Lung Cell Mol Physiol (Mar 2007) 16 [Electronic publication]
8. Velsor L.W., Kariya C., Kachadourian R., and Day B.J. Mitochondrial oxidative stress in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am J Respir Cell Mol Biol 35 5 (Nov 2006) 579-586
9. Day B.J. Glutathione: a radical treatment for cystic fibrosis lung disease?. Chest 127 1 (Jan 2005) 12-14
10. Day B.J., van Heeckeren A.M., Min E., and Velsor L.W. Role for cystic fibrosis transmembrane conductance regulator in a glutathione response to bronchopulmonary pseudomonas infection. Infect Immun 72 4 (Apr 2004) 2045-2051
11. Lands L.C., Grey V., Smountas A.A., Kramer V.G., and McKenna D. Lymphocyte glutathione levels in children with cystic fibrosis. Chest 116 1 (Jul 1999) 201-205
12. Cantin A.M., White T.B., Cross C.E., Forman H.J., Sokol R.J., and Borowitz D. Antioxidants in cystic fibrosis. Free Radic Biol Med 42 1 (Jan 1 2007) 15-31
13. Machen T.E. Innate immune response in CF airway epithelia: hyperinflammatory?. Am J Physiol Cell Physiol 291 2 (Aug 2006) C218-C230
14. Chen L., Patel R.P., Teng X., Bosworth C.A., Lancaster J.R., and Matalon S. Mechanisms of cystic fibrosis transmembrane conductance regulator activation by S-nitrosoglutathione. J Biol Chem 281 14 (Apr 7 2006) 9190-9199
15. Roum J.H., Buhl R., McElvaney N.G., Borok Z., and Crystal R.G. Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol 75 6 (Dec 1993) 2419-2424
16. Hudson V.M. Rethinking cystic fibrosis pathology: the critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation. Free Radic Biol Med 30 12 (Jun 15 2001) 1440-1461
17. Roum J.H., Borok Z., McElvaney N.G., Grimes G.J., Bokser A.D., Buhl R., and Crystal R.G. Glutathione aerosol suppresses lung epithelial surface inflammatory cell-derived oxidants in cystic fibrosis. J Appl Physiol 87 1 (Jul 1999) 438-443
18. Bishop C., Hudson V.M., Hilton S.C., and Wilde C. A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. Chest 127 1 (Jan 2005) 308-317
19. Tirouvanziam R., Conrad C.K., Bottiglieri T., Herzenberg L.A., Moss R.B., and Herzenberg L.A. High-dose oral N-acetylcysteine, a glutathione pro-drug, modulates inflammation in cystic fibrosis. PNAS USA 103 12 (Mar 21 2006) 4628-4633
20. Hartl D., Starosta V., Maier K., Beck-Speier I., Rebhan C., Becker B.F., et al. Inhaled glutathione decreases PGE2 and increases lymphocytes in cystic fibrosis lungs. Free Radic Biol Med 39 4 (Aug 15 2005) 463-472
21. Grey V., Mohammed S.R., Smountas A.A., Bahlool R., and Lands L.C. Improved glutathione status in young adult patients with cystic fibrosis supplemented with whey protein. J Cyst Fibros 2 4 (Dec 2003) 195-198
22. Griese M., Ramakers J., Krasselt A., Starosta V., Van Koningsbruggen S., Fischer R., et al. Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis. Am J Respir Crit Care Med 169 7 (Apr 1 2004) 822-828
23. Snyder A.H., McPherson M.E., Hunt J.F., Johnson M., Stamler J.S., and Gaston B. Acute effects of aerosolized S-nitrosoglutathione in cystic fibrosis. Am J Respir Crit Care Med 165 7 (Apr 1 2002) 922-926
24. Letter to Dr. Clark Bishop from the U.S. Food and Drug Administration, 17 July 2006, signed by Mary H. Parks, M.D., ODE II, CDER, in recipient's possession.
25. Peterson M.L., Jacobs Jr. D.R., and Milla C.E. Longitudinal changes in growth parameters are correlated with changes in pulmonary function in children with cystic fibrosis. Pediatrics 112 3 Pt 1 (Sep 2003) 588-592
26. Zemel B.S., Jawad A.F., FitzSimmons S., and Stallings V.A. Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation National CF Patient Registry. J Pediatr 137 3 (Sep 2000) 374-380
27. Thomson M.A., Quirk P., Swanson C.E., Thomas B.J., Holt T.L., Francis P.J., and Shepherd R.W. Nutritional growth retardation is associated with defective lung growth in cystic fibrosis: a preventable determinant of progressive pulmonary dysfunction. Nutrition 11 4 (Jul-Aug 1995) 350-354
28. Steinkamp G., and Wiedemann B. Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. Thorax 57 7 (Jul 2002) 596-601
29. Konstan M.W., Butler S.M., Wohl M.E., Stoddard M., Matousek R., Wagener J.S., Johnson C.A., and Morgan W.J. Investigators and coordinators of the epidemiologic study of cystic fibrosis. Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. J Pediatr 142 6 (Jun 2003) 624-630
30. Smyth R.L., Croft N.M., O'Hea U., Marshall T.G., and Ferguson A. Intestinal inflammation in cystic fibrosis. Arch Dis Child 82 5 (May 2000) 394-399
31. Investigator's brochure on oral reduced glutathione (GSH) (May 2007). http://members.tripod.com/uvicf/research/IBChartToggle.htm http://members.tripod.com/uvicf/research/IBChartToggle.htm
32. Griese, Matthias, "Efficacy and safety of inhaled glutathione in cystic fibrosis patients," http://clinicaltrials.gov/show/NCT00506688